Is ARCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARCT. It does not provide personalized investment advice.

ARCT (Arcturus Therapeutics Holdings Inc. Common Stock) Stock Analysis - Financials

Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) is a publicly traded Healthcare sector company. As of November 5, 2026, ARCT trades at $10.14 with a market cap of $308.96M and a P/E ratio of -3.91. ARCT moved -13.98% today. Year to date, ARCT is +46.30%; over the trailing twelve months it is +7.86%. Its 52-week range spans $5.50 to $24.17. Analyst consensus is strong buy with an average price target of $21.29. Rallies surfaces ARCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ARCT's key financials?

ARCT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ARCT recently traded at $10.14. Market cap is $308.96M. P/E ratio is -3.91. Revenue is $29.37M.

ARCT Key Metrics

Key financial metrics for ARCT
Metric	Value
Price	$10.14
Market Cap	$308.96M
P/E Ratio	-3.91
EPS	$-3.33
Dividend Yield	0.00%
52-Week High	$24.17
52-Week Low	$5.50
Volume	652.56K
Avg Volume	0
Revenue (TTM)	$29.37M
Net Income	$-93.28M
Gross Margin	0.00%

ARCT Analyst Consensus

9 analysts cover ARCT: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.29.

Common questions about ARCT

What are ARCT's key financials?: ARCT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ARCT recently traded at $10.14. Market cap is $308.96M. P/E ratio is -3.91. Revenue is $29.37M.
Is ARCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARCT. It does not provide personalized investment advice.